These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25456647)

  • 1. Sodium glucose cotransporter 2 inhibitors.
    White JR
    Med Clin North Am; 2015 Jan; 99(1):131-43. PubMed ID: 25456647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Lajara R
    Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
    Katz PM; Leiter LA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors.
    Dardi I; Kouvatsos T; Jabbour SA
    Biochem Pharmacol; 2016 Feb; 101():27-39. PubMed ID: 26362302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents.
    Choi CI
    Molecules; 2016 Aug; 21(9):. PubMed ID: 27618891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
    Cuypers J; Mathieu C; Benhalima K
    Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
    Girard J
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
    Vivian E
    Diabetes Educ; 2015 Dec; 41(1 Suppl):5S-18S. PubMed ID: 26450220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
    Albarrán OG; Ampudia-Blasco FJ
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canagliflozin: a novel treatment option for type 2 diabetes.
    Dietrich E; Powell J; Taylor JR
    Drug Des Devel Ther; 2013; 7():1399-408. PubMed ID: 24285921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans.
    Abdul-Ghani MA; DeFronzo RA; Norton L
    Diabetes; 2013 Oct; 62(10):3324-8. PubMed ID: 24065789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
    Whalen K; Miller S; Onge ES
    Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of SGLT2 inhibitors in managing type 2 diabetes.
    Tat V; Forest CP
    JAAPA; 2018 Jun; 31(6):35-40. PubMed ID: 29846314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy.
    Lapuerta P; Rosenstock J; Zambrowicz B; Powell DR; Ogbaa I; Freiman J; Cefalu WT; Banks P; Frazier K; Kelly M; Sands A
    Clin Cardiol; 2013 Jul; 36(7):367-71. PubMed ID: 23630033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
    Vallon V
    Annu Rev Med; 2015; 66():255-70. PubMed ID: 25341005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.